Compare with WYETH - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs WYETH - Comparison Results

WYETH 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES WYETH ALKEM LABORATORIES/
WYETH
 
P/E (TTM) x 24.4 27.7 87.9% View Chart
P/BV x 5.9 5.3 109.9% View Chart
Dividend Yield % 0.8 1.3 64.8%  

Financials

 ALKEM LABORATORIES   WYETH
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
WYETH
Mar-13
ALKEM LABORATORIES/
WYETH
5-Yr Chart
Click to enlarge
High Rs2,7201,044 260.4%   
Low Rs1,660818 203.0%   
Sales per share (Unadj.) Rs697.9298.6 233.7%  
Earnings per share (Unadj.) Rs96.157.2 167.9%  
Cash flow per share (Unadj.) Rs117.358.4 200.7%  
Dividends per share (Unadj.) Rs25.0017.00 147.1%  
Dividend yield (eoy) %1.11.8 62.5%  
Book value per share (Unadj.) Rs515.2249.5 206.5%  
Shares outstanding (eoy) m119.5722.72 526.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.13.1 100.6%   
Avg P/E ratio x22.816.3 140.1%  
P/CF ratio (eoy) x18.715.9 117.2%  
Price / Book Value ratio x4.33.7 113.9%  
Dividend payout %26.029.7 87.6%   
Avg Mkt Cap Rs m261,87921,157 1,237.8%   
No. of employees `00014.30.5 2,912.8%   
Total wages/salary Rs m15,055400 3,763.7%   
Avg. sales/employee Rs Th5,822.613,787.4 42.2%   
Avg. wages/employee Rs Th1,050.5813.0 129.2%   
Avg. net profit/employee Rs Th802.02,643.3 30.3%   
INCOME DATA
Net Sales Rs m83,4446,783 1,230.1%  
Other income Rs m1,042353 295.6%   
Total revenues Rs m84,4867,136 1,183.9%   
Gross profit Rs m14,7341,617 911.0%  
Depreciation Rs m2,52827 9,502.3%   
Interest Rs m6516 11,829.1%   
Profit before tax Rs m12,5981,938 650.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m1,105632 174.8%   
Profit after tax Rs m11,4931,301 883.7%  
Gross profit margin %17.723.8 74.1%  
Effective tax rate %8.832.6 26.9%   
Net profit margin %13.819.2 71.8%  
BALANCE SHEET DATA
Current assets Rs m54,9606,984 787.0%   
Current liabilities Rs m32,4332,056 1,577.6%   
Net working cap to sales %27.072.6 37.2%  
Current ratio x1.73.4 49.9%  
Inventory Days Days8099 80.2%  
Debtors Days Days7224 301.4%  
Net fixed assets Rs m32,710244 13,389.2%   
Share capital Rs m239227 105.2%   
"Free" reserves Rs m61,3685,441 1,127.9%   
Net worth Rs m61,6075,668 1,086.9%   
Long term debt Rs m1,59225 6,369.6%   
Total assets Rs m99,4337,901 1,258.5%  
Interest coverage x20.4353.3 5.8%   
Debt to equity ratio x00 586.0%  
Sales to assets ratio x0.80.9 97.7%   
Return on assets %12.216.5 73.9%  
Return on equity %18.722.9 81.3%  
Return on capital %21.034.0 61.6%  
Exports to sales %19.10.2 8,742.9%   
Imports to sales %3.036.3 8.2%   
Exports (fob) Rs m15,91715 107,548.0%   
Imports (cif) Rs m2,4832,465 100.7%   
Fx inflow Rs m16,06115 105,665.8%   
Fx outflow Rs m2,4832,677 92.7%   
Net fx Rs m13,578-2,662 -510.1%   
CASH FLOW
From Operations Rs m5,851923 633.8%  
From Investments Rs m-7,414317 -2,339.4%  
From Financial Activity Rs m792-481 -164.6%  
Net Cashflow Rs m-731759 -96.3%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 33.1 11.3 292.9%  
FIIs % 0.0 7.2 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 30.4 -  
Shareholders   68,381 21,978 311.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Lower; Dow Futures Down by 101 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading up by 357 points, up 0.7% at 49,267 levels.

Related Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 22, 2021 03:04 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS